• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

    3.110 +1.110 (+55.50%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Esperion Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    Veeva Systems, Five9, AXT And Other Big Stocks Moving Higher On Friday ↗
    US stocks were mixed on Friday, with Dow Jones down 0.1%. Veeva Systems Inc (NYSE: VEEV) rose 11.6%, joining S&P 500 on May 7. Other big gainers: Esperion Therapeutics Inc (NASDAQ: ESPR), Five9 Inc... 
    Via Benzinga
    Topics Artificial Intelligence Stocks
    Friday's session: most active stocks ↗
    Via Chartmill
    Which stocks are moving on Friday? ↗
    Via Chartmill
    Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q4 2025 Results Amid Strategic Expansion ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Esperion to be Acquired by ARCHIMED
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Report First Quarter 2026 Financial Results on May 7
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
    From Athyrium Capital Management, LP
    Via GlobeNewswire
    News headline image
    Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗
    Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million. 
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
    From Corstasis Therapeutics Inc.
    Via Business Wire
    News headline image
    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in The 2026 Citizens Life Sciences Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug ↗
    Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage. 
    Via Stocktwits
    News headline image
    Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.